Noventure and RFSU enter into agreement to commercialize Utipro® Plus across Nordic countries
Barcelona, March 13, 2017 - Noventure and Riksförbundet för sexuell upplysning (RFSU), the Swedish Association for Sexuality Education, announce today that they have entered into an agreement by which RFSU will distribute Noventure’s Utipro® Plus in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). With this agreement, Utipro Plus is now available in 21 European countries.
Utipro Plus is a Class III CE marked medical device used to control and prevent uncomplicated urinary tract infections (UTIs) by relieving associated symptoms in the acute phase of the pathology as well as preventing relapses. Utipro Plus is available in capsules for oral use.
UTIs are infections of the lower urinary system resulting from the increased proliferation and ascent of intestinal bacteria. These contaminate the distal urethra and reach the bladder causing irritating symptoms such as dysuria, frequency, urgency, pain and bladder tenderness. Relapses are caused by the presence of bacterial reservoirs.
UTIs are among the most prevalent infectious diseases affecting women worldwide: approximately 13% of women between the age of 18 and 90 will have an annual incidence of UTI.
Luciano Conde, CEO of Noventure said: “Utipro Plus offers an innovative approach to UTIs. After a successful introduction in other European countries, it can now help improve the wellbeing of women across the Nordic countries. This agreement with RFSU, a recognized leader in promoting women’s health in the region, is an exciting opportunity for Noventure.”
Katarina Knutz, CEO of RFSU AB said: “We are delighted to partner with Noventure and to be able to offer Utipro Plus, a unique product, to Nordic consumers. The benefit of preventing and relieving the symptoms of UTIs, reducing the usage of antibiotics, will be highly appreciated both by the physicians and patients. We see Utipro Plus as a product that will greatly improve women’s health.”
Norgine and Noventure enter into an agreement to commercialise Gelsectan® in Spain, Portugal and Andorra
Barcelona, March 6, 2017 - Norgine B.V. and Noventure S.L. announce today that they have entered into an agreement by which Norgine will distribute Noventure’s Gelsectan® in Spain, Portugal and Andorra.
Gelsectan is a Class IIa CE marked medical device used to restore the intestinal function in patients suffering from alterations due to irritable bowel syndrome (IBS) with relapsing or chronic diarrhoea, a symptom often associated with IBS by relieving associated symptoms, such as pain, abdominal tension, diarrhoea, bloating and flatulence.
Gelsectan is available in capsules for oral use.
IBS is a disorder characterised by abdominal discomfort associated with altered bowel function. It is estimated that 10-15 per cent of the global population has IBS, while it affects up to 7.8 per cent of the total Iberian population (Spain, Portugal and Andorra), where more than 100.000 new cases are reported every year1. Women are twice as likely as men to develop IBS2.
Peter Martin, COO at Norgine said: “We are delighted to be able to offer Gelsectan, a new treatment option to patients who suffer from irritable bowel syndrome associated with diarrhoea, a condition which can have a significant impact on quality of life. This recent partnership demonstrates our commitment to sell further specialised innovative products through our well established infrastructure.”
Efficacy and safety of APT198K for the treatment of infantile colic: a pilot study
We are pleased to inaugurate the new year with a publication of great importance: last January 24th on the Journal of Effectiveness Research, the article "Efficacy and safety of APT198K for the treatment of infantile colic: a pilot study" was published. The study supports safety and efficacy of Aprotecol, a product intended to solve infant colic, and it was signed by a KOL in Europe, Professor Yvan Vandenplas, Head of the department of Pediatrics of the Vrije Universiteit Brussel in Belgium.
Outcomes of the study clearly demonstrated the efficacy of our product in reducing the number and the duration of the crying crisis in colicky infants for which, until now, no efficient remedy was available.